Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD Nexalin Technology (Nasdaq: NXL) announced a peer‑reviewed, randomized double‑blind sham‑controlled trial published in Molecular Psychiatry showing four weeks of its non‑invasive DIFS™ neurostimulation improved attention and normalized brain activity in adults with ADHD.In 56 adults, active treatment produced a 10.1‑point average improvement on the Adult ADHD Self‑Report Scale versus 5.5‑points for sham (4.6‑point separation, p < 0.001), plus MEG/EEG evidence of reduced excessive gamma activity and restored network communication. Treatment was well tolerated with no serious adverse events reported.

#NXL #NXLIW Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

www.stocktitan.net/news/NXL/published-peer-...

#NXL #NXLIW Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program

www.stocktitan.net/news/NXL/nexalin-technol...

#NXL #NXLIW Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4

www.stocktitan.net/news/NXL/join-nexalin-te...

Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity Nexalin Technology (Nasdaq: NXL) reported a peer-reviewed case report in The American Journal on Addictions showing promising results using its 15 mA neurostimulation device to treat gambling disorder comorbid with alcohol use disorder.In a single patient treated at Shanghai Mental Health Center, 20 outpatient sessions over 10 days (15 mA at 77.5 Hz for 40 minutes each) produced complete abstinence from gambling and alcohol, improved cognitive control, and no adverse effects during a three-month follow-up. The study (ClinicalTrials.gov NCT06195995) received ethics approval. The device is approved in China for depression and insomnia. Authors recommend larger controlled trials to confirm findings.

#NXL #NXLIW Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

www.stocktitan.net/news/NXL/nexalin-s-15-mi...

Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia Nexalin Technology (Nasdaq: NXL) announced that the U.S. Food and Drug Administration accepted its Q-Submission for the Gen-2 SYNC console for treatment of Alzheimer’s disease and dementia on November 5, 2025.The acceptance schedules a regulatory meeting later in 2025 to discuss clinical trial design, endpoints, statistical plans and the regulatory pathway toward a potential U.S. Investigational Device Exemption (IDE).Company-reported supportive signals include encouraging internal data, published studies showing improved cognitive performance, no serious adverse events across international use, and EEG/qEEG evidence of waveform-induced neural connectivity changes for dementia-related conditions.

#NXL #NXLIW Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia

www.stocktitan.net/news/NXL/nexalin-technol...

Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies Nexalin Technology, Inc. (Nasdaq:

#NXL #NXLIW Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies

www.stocktitan.net/news/NXL/nexalin-s-difst...

Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device Nexalin Technology (Nasdaq: NXL) reported peer-reviewed clinical results (Radiology, Oct 8, 2025) showing its Gen-2 SYNC 40-Hz, 15 mA DIFS neurostimulation device produced statistically significant cognitive gains and measurable brain-connectivity changes in mild Alzheimer’s disease.Key findings: significant MMSE and MoCA score improvements versus sham (P = .001 and .03), increased hippocampal-cortical and network functional connectivity on resting-state fMRI, a connectivity–naming-test correlation (r = 0.65, FDR-adjusted P = .008), and no reported adverse events. Device has regulatory approvals for other indications in China, Brazil, and Oman.

#NXL #NXLIW Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device

www.stocktitan.net/news/NXL/nexalin-technol...

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology Nexalin Technology (NASDAQ: NXL) has secured U.S. Design Patent No. D1,092,758 for its HALO™ Clarity neuromodulation device, providing 15 years of design protection. The device utilizes the company's proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology to deliver non-invasive, drug-free treatment for mental health and neurological conditions.The HALO™ Clarity system enables at-home, professionally supervised treatment with remote monitoring capabilities. The company is conducting multiple clinical studies across various indications including anxiety, insomnia, PTSD, and mild traumatic brain injury. The FDA has already provided consensus on pivotal trial designs for anxiety and insomnia indications.The DIFS™ platform has demonstrated safety and efficacy signals in over two dozen trials worldwide. Nexalin has completed usability, safety, and design verification testing and is scaling manufacturing for broader clinical deployment.

#NXL #NXLIW Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology

www.stocktitan.net/news/NXL/nexalin-technol...

$537B Mental Health Market: Nexalin Tech Showcases AI-Powered Brain Stimulation Platform for Home Use Nexalin CEO to discuss DIFS technology, Gen-3 HALO Clarity headset, and Virtual Clinic model on Sept 9. Features UC San Diego collaboration, international approvals, and AI monitoring advances.

#NXL #NXLIW Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9

www.stocktitan.net/news/NXL/join-nexalin-te...

Revolutionary Mental Health Tech: Nexalin Unveils Game-Changing Treatment in $537B Market Webinar Get exclusive insights into Nexalin's breakthrough DIFS technology and Gen-3 HALO headset revolutionizing mental health treatment. Join CEO presentation June 3.

#NXL #NXLIW Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3

www.stocktitan.net/news/NXL/join-nexalin-te...

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the pricing of an underwritten public offering of 3,850,000 shares of its common stock

#NXL #NXLIW Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

www.stocktitan.net/news/NXL/nexalin-technol...

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback Nexalin Technology (NASDAQ: NXL) has announced plans to submit a Q-Submission to the FDA for its Gen-2 SYNC system, marking a crucial step in its regulatory pathway. The Q-Sub aims to facilitate discussions with the FDA regarding clinical trial design for treating Alzheimer's disease, dementia, and mild cognitive impairment (MCI).This decision follows encouraging internal data and preliminary FDA feedback. The Gen-2 SYNC system features technical improvements, including a redesigned enclosure and integration of Nexalin's proprietary 15 milliamp advanced waveform. The company is also undertaking a rebranding initiative to differentiate this system from previous versions.

#NXL #NXLIW Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

www.stocktitan.net/news/NXL/nexalin-technol...

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia Nexalin Technology (Nasdaq: NXL) has received institutional review board (IRB) approval in Brazil to begin a Phase II clinical trial for its Gen-2 neurostimulation device. The study will evaluate the treatment of anxiety disorders and chronic insomnia at the Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo.The trial will enroll 30 adult patients to assess the efficacy of Nexalin's Deep Intracranial Frequency Stimulation (DIFS™) technology. The primary endpoint will measure anxiety reduction using the Hamilton Anxiety Rating Scale (HAM-A), with secondary endpoints including assessments of depression symptoms, sleep quality, and clinical improvement.Led by Dr. Andre Russowsky Brunoni, the study marks Nexalin's first IRB-approved trial in Brazil. The first device has been shipped to São Paulo, with additional units and disposable electrodes scheduled for delivery soon. Results will be published in a peer-reviewed scientific journal.

#NXL #NXLIW Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

www.stocktitan.net/news/NXL/nexalin-technol...

Advanced AI Virtual Clinic Powers Groundbreaking Military PTSD Study: Nexalin's New Digital Health Platform New AI-driven platform enables at-home brain stimulation therapy for military personnel. Remote monitoring system tracks real-time treatment data. Learn more.

#NXL #NXLIW Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

www.stocktitan.net/news/NXL/nexalin-technol...

New Healthcare Bill Could Unlock 5-Year Medicare Coverage for AI Mental Health Devices, Nexalin Advances AI Platform Latest bipartisan bill proposes 5-year Medicare coverage for AI-enabled medical devices. Nexalin positions AI mental health platform for reimbursement pathway. Learn more.

#NXL #NXLIW Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

www.stocktitan.net/news/NXL/nexalin-technol...

Game-Changing Patent: Nexalin's Brain Stimulation Tech Takes On $35B Addiction Treatment Market Revolutionary non-invasive brain stimulation technology targets substance abuse disorders without drugs. Patent strengthens Nexalin's position in addiction treatment. Full analysis inside.

#NXL #NXLIW Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

www.stocktitan.net/news/NXL/nexalin-technol...

Revolutionary Brain Treatment: Nexalin Launches PTSD Trial at UCSD with AI-Powered Home Therapy Advanced DIFS™ technology now treating PTSD/TBI patients through AI-monitored home therapy. Partnership with UCSD and VA marks major milestone. See trial details inside.

#NXL #NXLIW Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

www.stocktitan.net/news/NXL/nexalin-technol...

Revolutionary Brain Tech Targets $537B Market: Nexalin CEO Reveals Growth Strategy Discover Nexalin's breakthrough brain stimulation technology for PTSD and TBI treatment. CEO presents clinical data and Gen-3 HALO innovation. Full analysis inside.

#NXL #NXLIW Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3

www.stocktitan.net/news/NXL/join-nexalin-te...

Can Nexalin's Brain Stimulation Technology Transform PTSD Treatment? UCSD Trial Now Recruiting Patients Non-invasive deep brain stimulation technology enters clinical testing for trauma-related conditions with remote monitoring capabilities, offering drug-free treatment potential.

#NXL #NXLIW Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval

www.stocktitan.net/news/NXL/nexalin-technol...

Revolutionary Brain Treatment Device Enters Military PTSD Trials at UCSD - Potential Breakthrough for Veterans Major clinical trial approved: UCSD to evaluate Nexalin's AI-powered HALO device for treating PTSD and brain injuries in military personnel using groundbreaking technology

#NXL #NXLIW Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

www.stocktitan.net/news/NXL/nexalin-technol...

Nexalin Tech CEO to Showcase Revolutionary Brain Treatment Device in Exclusive Investor Webinar Join Nexalin's CEO Mark White on Jan 23 as he reveals breakthroughs in non-invasive brain stimulation technology targeting $537B market for insomnia, PTSD & brain injuries.

#NXL #NXLIW Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23

www.stocktitan.net/news/NXL/join-nexalin-te...

Nexalin's Revolutionary DIFS Technology Shows 65% Success Rate in Depression Treatment Nexalin's Gen-3 Halo headset delivers breakthrough results in mental health treatment with proprietary technology 10x more powerful than competitors, backed by 29 clinical trials.

#NXL #NXLIW Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025

www.stocktitan.net/news/NXL/nexalin-technol...

Nexalin Launches AI-Powered Virtual Clinic Platform for Remote Mental Health Treatment Trials Nexalin Technology completes Phase 1 of its AI-integrated virtual clinic system, enabling remote clinical trials and treatment monitoring for mental health conditions.

#NXL #NXLIW Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

www.stocktitan.net/news/NXL/nexalin-technol...